Tag Archives: subretinal implant

Science Research Technology

Specialists discuss visual prostheses for blind people

Retina Implant AG at „Artificial Vision 2017“ research congress in Aachen

Specialists discuss visual prostheses for blind people

Dr. Alfred Stett, CTO Retina Implant AG (Source: Retina Implant AG)

(Reutlingen/Aachen) – Retina Implant AG presented the latest research results on its subretinal implant at the „Artificial Vision“ conference in Aachen in early December. This international symposium on visual prostheses is organised by RWTH Aachen University. It is regarded as an unmissable European event for specialists in the field of „artificial vision“.

Research into artificial vision using prostheses has been under way since the 1960s. Following initial promising findings in the 1990s, major technological advances have led to further tangible results in the last few years. As early as 2008, a previously completely blind patient was able to make out his name, written in 8 cm white letters on a black background, using the subretinal implant from Reutlingen-based Retina Implant AG. Since then, the expectations placed on the electronic implants have increased continuously. Most patients with an implanted chip can identify light sources, which makes it easier for them, for example, to find their way around a room again.

„Now our job is to meet the high expectations raised by our initial successes,“ explained Dr. Alfred Stett, CTO of Retina Implant AG. „We“ve been able to sufficiently prove that our implant can restore partial sight to people who perceive very little or no light as a result of retinitis pigmentosa. At „Artificial Vision“, we had extensive discussions about the technical and medical challenges that still need to be overcome.“ These include the service life of implants, which need to function in the body without a hermetic casing over many years, vision-training and rehabilitation after the implant has been activated as well as re-implantations. „Once again, the symposium showed there is now a very wide range of different technical and surgical methods for implants. However, the experts all agreed that visual prostheses offer real prospects for patients who became blind as a result of a degenerative retinal disease.“

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Volker Hiller
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 282
E-Mail: volker.hiller@retina-implant.de
Url: https://www.retina-implant.de/en/

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

Reimbursement of retinal implant for a limited number of patients

French health authority HAS approves Forfait Innovation application by Retina Implant AG

Reimbursement of retinal implant for a limited number of patients

(Source: Retina Implant AG)

(Reutlingen, Germany/Saint-Denis, France) – French health authority HAS (Haute Autorite de Sante) has just approved the Forfait Innovation application by Retina Implant AG to assess the benefits of its RETINA IMPLANT Alpha AMS subretinal implant. The procedure evaluates innovative technologies in the healthcare sector to quickly make them available to patients. As part of the Forfait Innovation process, over a two-year period the costs will be covered for the implant and treatment of a limited number of patients who perceive little or no light. Retina Implant AG fund the costs for the accompanying study, which is examining the impact of the implant on participants` daily lives (Impact on daily life of patients using the subretinal implant RETINA IMPLANT Alpha AMS).

Following the successful conclusion of the study, the implant will be added to the list of approved services of health insurance companies in France. As a result of the reimbursement, an innovative technology can be made available to patients with the hereditary retinal disease retinitis pigmentosa (RP), which leads to total blindness in the final stage. Although RP is a rare disease, some 130,000 people suffer from it in Europe alone. The subretinal implant is virtually invisible except for a small transponder fixed behind the ear. The implant can partially restore the sight of blind people suffering from RP. This means a large proportion of patients can make out light sources with the RETINA IMPLANT Alpha AMS and thus find their way around a room, for example.

„For some time now, work has been in progress to focus attention on the practical benefits for visually impaired people in their everyday lives, alongside standard sight measurements. We`re delighted this study is taking particular account of this aspect,“ explains Jürgen Klein, Sales and Marketing Director at Retina Implant AG. „France is therefore taking a leading role in Europe in evaluating subretinal implants.“ The study will be performed in close cooperation between the university hospital CHU Montpellier for screening and patient follow-up and the implantation centre Clinique St Jean in Montpellier for the surgery, with further centres planned.

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Ines Wülker
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 289
E-Mail: ines.wuelker@retina-implant.de
Url: http://implant.de

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

Initial results of RETINA IMPLANT Alpha AMS trial published

New study on functionality of Retina Implant AG´s subretinal implant in Frontiers in Neuroscience

Initial results of RETINA IMPLANT Alpha AMS trial published

(Source: Retina Implant AG)

(Reutlingen) – The scientific journal Frontiers in Neuroscience has published a report on the functionality of Retina Implant AG´s RETINA IMPLANT Alpha AMS subretinal implant. The joint article by a group of experts headed by Eberhart Zrenner, Senior Professor of Ophthalmology at the Werner Reichardt Centre for Integrative Neuroscience, which forms part of the Institute for Ophthalmic Research at the Eberhard Karls University of Tübingen, relates to clinical experience with a group of patients who had the latest version of the chip implanted at various hospitals in Europe.

In the article, entitled „Interim Results of a Multicenter Trial with the New Electronic Subretinal Implant Alpha AMS in 15 Patients Blind from Inherited Retinal Degenerations“, lead author Dr.Katharina Stingl from the Tübingen Institute for Ophthalmic Research and other doctors and scientists involved in the trial describe how the chip performed.

Study:
Stingl K., Schippert R., Bartz-Schmidt K. U., Besch D., Cottriall C. L., Edwards T. L., Gekeler F., Greppmaier U., Kiel K., Koitschev A., Kühlewein L., MacLaren R. E., Ramsden J. D., Roider J., Rothermel A., Sachs H., Schröder G. S., Tode J., Troelenberg N. and Zrenner E. (2017): Interim Results of a Multicenter Trial with the New Electronic Subretinal Implant Alpha AMS in 15 Patients Blind from Inherited Retinal Degenerations. Frontiers in Neuroscience. 11:445. doi: 10.3389/ fnins.2017.00445.
http://journal.frontiersin.org/article/10.3389/fnins.2017.00445/full

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the dis-ease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member ot the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Ines Wülker
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 289
E-Mail: ines.wuelker@retina-implant.de
Url: http://implant.de

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de